Trends in Molecular Medicine Journal Impact Factor & Information

Publisher: Elsevier

Journal description

Trends in Molecular Medicine's objective is to facilitate communication between groups of highly trained professionals with distinct backgrounds and skills, whose common goals are to understand and explain the molecular basis of disease with a view to new clinical practice. Trends in Molecular Medicine is a resource for students and professionals alike, who have information needs that transcend the traditional clinical or scientific categorisation. Trends in Molecular Medicine includes review articles on the genetic basis of disease, but 'molecular' does not only mean DNA. The diagnostic role of genetic processes is clear, but major benefits in health and disease are also provided by other molecules: enzymes, antibiotics, hormones, metals, carbohydrates, lipids, vitamins, synthetic organic and inorganic polymers. Such benefits are discussed and evaluated by Trends in Molecular Medicine. Furthermore 'Medicine' involves a vital societal element; molecular intervention raises controversial ethical, legal and financial issues. All these issues are addressed in Trends in Molecular Medicine in a style that builds on 25 years' experience of publishing the Trends Journals.

Current impact factor: 10.11

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 10.11
2012 Impact Factor 9.571
2011 Impact Factor 10.355
2010 Impact Factor 10.308
2009 Impact Factor 11.049
2008 Impact Factor 9.621
2007 Impact Factor 7.244
2006 Impact Factor 5.864
2005 Impact Factor 5.505
2004 Impact Factor 7.497
2003 Impact Factor 9.848
2002 Impact Factor 7.162
2001 Impact Factor

Impact factor over time

Impact factor
Year

Additional details

5-year impact 10.14
Cited half-life 5.40
Immediacy index 1.49
Eigenfactor 0.02
Article influence 3.84
Website Trends in Molecular Medicine website
Other titles Trends in molecular medicine (Online)
ISSN 1471-4914
OCLC 45949985
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Elsevier

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • On authors personal or authors institutions server
    • Published source must be acknowledged
    • Must link to journal home page
    • Publisher's version/PDF cannot be used
    • 'Elsevier (Cell Press)' is an imprint of 'Elsevier'
  • Classification
    ​ blue

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Optimally, any prescription should rely on an in-depth understanding of the disease biology and the mechanism of action of the drug. However, despite the hype about precision medicine in recent years, the prescription of most drugs is still, except for a few anticancer drugs, largely based on 'trial and error' and not on solid pharmacogenomic biomarker data. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Trends in Molecular Medicine 07/2015; 21(7). DOI:10.1016/j.molmed.2015.05.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Crowdsourcing presents a novel approach to solving complex problems within molecular medicine. By leveraging the expertise of fellow scientists across the globe, broadcasting to and engaging the public for idea generation, harnessing a scalable workforce for quick data management, and fundraising for research endeavors, crowdsourcing creates novel opportunities for accelerating scientific progress. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Trends in Molecular Medicine 07/2015; 21(7). DOI:10.1016/j.molmed.2015.05.001
  • [Show abstract] [Hide abstract]
    ABSTRACT: INPP4B acts as a tumor suppressor in various epithelial cancers by inhibiting PI3K/Akt signaling. Unexpectedly, tumor-promoting features of INPP4B in leukemia and breast cancer have been recently uncovered. In this spotlight, we discuss the seemingly paradoxical nature of INPP4B-mediated signaling in cancer. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Trends in Molecular Medicine 07/2015; DOI:10.1016/j.molmed.2015.06.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many organs throughout the body maintain epithelial homeostasis by employing a mucosal barrier which acts as a lubricant and helps to preserve a near-sterile epithelium. Goblet cells are largely responsible for secreting components of this mucosal barrier and represent a major cellular component of the innate defense system. In this review we summarize what is known about the signaling pathways that control goblet cell differentiation in the intestine, the lung, and the ocular surface, and we discuss a novel functional role for goblet cells in mucosal epithelial immunology. We highlight the cell type-specificity of the circuitry regulating goblet cell differentiation and shed light on how changes to these pathways lead to altered goblet cell function, a prominent feature of mucosa-associated diseases. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Trends in Molecular Medicine 07/2015; DOI:10.1016/j.molmed.2015.06.003
  • [Show abstract] [Hide abstract]
    ABSTRACT: Placebos are indispensable controls in randomized clinical trials (RCTs), and placebo responses significantly contribute to routine clinical outcomes. Recent neurophysiological studies reveal neurotransmitter pathways that mediate placebo effects. Evidence that genetic variations in these pathways can modify placebo effects raises the possibility of using genetic screening to identify placebo responders and thereby increase RCT efficacy and improve therapeutic care. Furthermore, the possibility of interaction between placebo and drug molecular pathways warrants consideration in RCT design. The study of genomic effects on placebo response, 'the placebome', is in its infancy. Here, we review evidence from placebo studies and RCTs to identify putative genes in the placebome, examine evidence for placebo-drug interactions, and discuss implications for RCTs and clinical care. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Trends in Molecular Medicine 04/2015; in press(5). DOI:10.1016/j.molmed.2015.02.009
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sophistication in DNA and RNA sequencing technology is unraveling the tremendous genetic and molecular complexity of human cancer. However, the rate at which this knowledge is being translated into patient care is too slow. To this end, we have designed and implemented a new translational platform, 'The Co-Clinical Trial Project', where data obtained in genetically engineered mouse models (GEMMs) of human cancer treated with protocols identical to those of ongoing clinical trials or with therapies already established in patients serve to rapidly: (i) stratify patients in terms of response and resistance on the basis of genetic and molecular criteria; (ii) identify mechanisms responsible for tumor resistance; and (iii) evaluate the effectiveness of drug combinations to overcome such resistance based on mechanistic understanding. Copyright © 2014. Published by Elsevier Ltd.
    Trends in Molecular Medicine 11/2014; 21(1). DOI:10.1016/j.molmed.2014.10.008
  • [Show abstract] [Hide abstract]
    ABSTRACT: Small intestine bacterial overgrowth (SIBO) occurs when colonic quantities of commensal bacteria are present in the small bowel. SIBO is associated with conditions of disrupted GI motility leading to stasis of luminal contents. Recent data show that SIBO is also found in children living in unsanitary conditions that do not have access to clean water. SIBO leads to impaired micronutrient absorption and increased GI permeability, both of which may contribute to growth stunting in children. SIBO also disrupts mucosal immunity and has been implicated in oral vaccination underperformance and the development of celiac disease. SIBO in the setting of the impoverished human habitat may be an under recognized cause of pediatric morbidity and mortality in the developing world.
    Trends in Molecular Medicine 11/2014; 21(1). DOI:10.1016/j.molmed.2014.11.001